Life AI Net
ホーム
アーカイブ
計算ツール
ディレクトリ
ニュースレター
Hot
ログイン
日本語
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
ホーム
アーカイブ
計算ツール
ディレクトリ
ニュースレター
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
ログイン
ホーム
アーカイブ
計算ツール
ディレクトリ
More
ライブ
FierceBiotech
Pulnovo Medical scores $100M in finance round led by Medtronic
Lonza News
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
10x Genomics Blog
Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.st
Brady Corporation
Milwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
BioWorld
Pricing standoff leaves Australian patients in limbo
BioWorld
Mabwell turns to Hong Kong to fund ADC ambitions
BioWorld
Xuanzhu shares dip despite phase III ALK inhibitor data
FierceBiotech
Pulnovo Medical scores $100M in finance round led by Medtronic
Lonza News
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
10x Genomics Blog
Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.st
Brady Corporation
Milwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
BioWorld
Pricing standoff leaves Australian patients in limbo
BioWorld
Mabwell turns to Hong Kong to fund ADC ambitions
BioWorld
Xuanzhu shares dip despite phase III ALK inhibitor data
アーカイブ
BioWorld
2026年3月13日
In the clinic for March 13, 2026
In the clinic for March 13, 2026
原文
本文は利用できません。元の情報源をご確認ください。